Where does Ascentage Pharma Group Corp Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ascentage Pharma Group Corp Limited ranks #13,870 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ascentage Pharma Group Corp Limited hold?

Ascentage Pharma Group Corp Limited holds 21 US utility patents granted between 2022 and 2025, spanning 9 technology areas.

What is Ascentage Pharma Group Corp Limited's Innovation Score?

Ascentage Pharma Group Corp Limited has an Innovation Score of 52.0 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ascentage Pharma Group Corp Limited focus on?

Ascentage Pharma Group Corp Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 17 patents, ranking #1,155 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Ascentage Pharma Group Corp Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Ascentage Pharma Group Corp Limited.

What does claim depth mean for Ascentage Pharma Group Corp Limited's patents?

Ascentage Pharma Group Corp Limited's patents average 17.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ascentage Pharma Group Corp Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ascentage Pharma Group Corp Limited

USPTO PatentsView assignee record - 21 granted patents across 9 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ascentage ranks #13,870 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 9 technology areas.

#13,870
of 49,997 US assignees by volume: Top 11%
by Innovation Score (52.0/100): 17.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R13870 · Foreign Corporation #13,870 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 21 grants
MID-PACK #13,870/49,997
PHOTO-FINISH Acerta Pharma B V
CPC-NARROW A61P · 9 areas
INNOV-PAR 52.0/100
CLAIMS-RICH 17.9 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Acerta Pharma B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ascentage’s 52.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (21%) Velocity 20.0 pts (38%) Breadth 10.6 pts (20%) Claim depth 10.7 pts (21%)

Qualcomm Incorporated · highest

85
Advantest Test… · near

52
Chr Hansen HMO · near

52
Latham Pool Products · near

52
Unifrax I · near

52
Ascentage Pharma Group · this assignee

52
3D Lighting… · lowest

7

What this shows Ascentage's Innovation Score is 52.0/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ascentage?

Each dot is one of Ascentage’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ascentage’s own 17.9 claims/patent is ABOVE the 15.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ascentage vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ascentage's grants concentrate

Ascentage Pharma Group Corp Limited is a focused PatentsView assignee: 9 CPC subclasses with 81% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (6 grants) versus a trough of 3 in 2023. By volume, Ascentage sits between Applied Medical Technology, Inc. and Acerta Pharma B.V..

Ascentage's three-year grant acceleration

Ascentage Pharma Group Corp Limited shows 13 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Applied Medical T…

21
Aprecia Pharmaceu…

21
ARB Labs

21
Artika FOR Living

21
Asterias Biothera…

21
Atlas Copco Airpo…

21
Avantec Vascular

21
Acerta Pharma B V

21
Ascentage Pharma… ◀

21

What this shows Ascentage holds 21 patents at rank #13,847, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ascentage

By rank, the assignees closest to #13,847 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Ascentage's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Ascentage, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Ascentage ranks #1,155 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (52 here).

Chr. Hansen HMO GmbH 52 Latham Pool Products, Inc. 52 Advantest Test Solutions, Inc. 52 Unifrax I LLC 52

Ascentage's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Ascentage Pharma Group Corp Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	6	28.6%
2023	3	14.3%
2024	4	19.0%
2025partial year	8	38.1%

Which technologies does Ascentage Pharma Group Corp Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 17

C07D - Heterocyclic Compounds 15

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07C - Acyclic OR Carbocyclic Compounds 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ascentage Pharma Group Corp Limited's patent record in context - here's where to go next.

Ascentage Pharma Group Corp Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 81% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #13,870 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ascentage Pharma Group Corp Limited against Applied Medical Technology, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 52.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.